348. Correction of CNS and Somatic Pathology by Intra-Cerebrospinal Fluid Gene Therapy for Mucopolysaccharidosis Type II

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)33157-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Mucopolysaccharidosis Type II: Enzyme Replacement Therapy Efficiency

Voprosy Sovremennoi Pediatrii - Current Pediatrics
Child HealthPediatricsPerinatology
2020English

Physiology and Pathology of the Cerebrospinal Fluid.

JAMA - Journal of the American Medical Association
Medicine
1921English

20. Development of Lentiviral Mediated Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIA

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Pharmacoeconomic Evaluation of Drugs Used in Enzyme Replacement Therapy Mucopolysaccharidosis Type II

Pharmacoeconomics: theory and practice
2019English

Cerebrospinal Fluid Analysis in the Context of CNS Demyelinating Diseases

Arquivos de Neuro-Psiquiatria
Biological PsychiatryNeurology
2013English

Arterial Pathology in Canine Mucopolysaccharidosis-I and Response to Therapy

Laboratory Investigation
Forensic MedicinePathologyCell BiologyMolecular Biology
2011English

Therapy of Malignant Intracranial Hypertension by Lumbar Cerebrospinal Fluid Drainage

Critical Care
Critical CareIntensive Care Medicine
2000English

Gene Therapy for CNS Diseases – Krabbe Disease

BioImpacts
BiochemistryMedicineGeneticsMolecular BiologyPharmaceutical Science
2016English

Viral Vectors and Delivery Strategies for CNS Gene Therapy

Therapeutic Delivery
Pharmaceutical Science
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy